Thrombolytic Science International (TSI), a clinical stage vascular health and biotechnology company, announced the appointment of Annalisa Jenkins, MBBS, FRCP, formerly President and CEO of Dimension Therapeutics, as a non-executive board member.
Dr Jenkins brings more than 25 years of global pharmaceutical industry experience to TSI’s Board of Directors.
"Dr Jenkins has a proven track record of successfully translating exciting science from bench to bedside," said Dr Michael Woehler, Chairman of TSI.
"We are pleased to welcome Annalisa to our board at an important time for the company, where her extensive and broad experience in all aspects of biotechnology, drug development and M&A will prove invaluable."
TSI recently completed of a Phase 1 clinical trial of TS01, a new-generation clot-dissolving therapy mimicking nature’s safe and efficient fibrinolytic system, which is aimed at the treatment of clot-induced diseases. The first-in-man randomised, double-blind, placebo-controlled study demonstrated the overall safety and tolerability of TS01 in healthy adults. The Company is now preparing to enter human proof of concept trials in ischemic stroke and myocardial infraction.
"I look forward to Dr Jenkins’ contributions in advancing TS01 into phase 2 clinical trials and ensuring patient access to TSI’s pioneering fibrinolytic solution through biopharma collaborations," said Alexis C. Wallace, CEO of TSI.
Prior to joining TSI’s board of directors, Dr Jenkins served as President and CEO of Dimension Therapeutics, a leading gene therapy company that was acquired by Ultragenyx Pharmaceutical in November 2017.
Dr Jenkins previously held multiple leadership positions, including executive VP, head of Global Research and Development for Merck Serono, where she led Global Medical Affairs and Quality, and was a member of Merck Serono’s Pharmaceutical Executive Committee.
Prior to this, Dr Jenkins had a successful 14-year career at Bristol-Myers Squibb (BMS), attaining the role of senior VP and head of Global Medical Affairs.
During her tenure at BMS, Dr Jenkins played a key role in the development, approval, and/or commercialisation of products in multiple therapeutic areas, including cardiology, immuno-oncology, immunology and infectious diseases. Earlier in her career, Dr Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of Surgeon Lieutenant Commander.
Dr Jenkins graduated with a degree in medicine from St Bartholomew’s Hospital, University of London and subsequently trained in cardiovascular medicine in the UK National Health Service.
Dr Jenkins chairs the boards of Cell Medica, Silence Therapeutics and Vium, and is a Director on the boards of OncoSec, Ardelyx, Phesi, iOx and Cocoon. She is also a committee member of the Science Board to the US Food & Drug Administration (FDA), serves on the board of the Center for Talent Innovation (UK) and is on the Advisory Panel of the Healthcare Businesswomen's Association.
